Skip to content

Comparison of levobupivacaine with ropivacaine for painless labour

Comparison of 0.125% ropivacaine- dexmedetomidine with 0.125% levobupivacaine- dexmedetomidine for epidural labour analgesia

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/09/004007
Enrollment
50
Registered
2013-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Term Pregnant Female Parturients

Interventions

Intervention1: 10 ml of 0.125% of levobupivacaine with dexmedetomidine (0.5ug/kg body wt): In group II patients,10 ml of 0.125% of levobupivacaine with dexmedetomidine (0.5ug/kg body wt)will be inject

Sponsors

Dr T S Punia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Singleton Healthy Full Term Pregnancy ASA physical status I or II

Exclusion criteria

Exclusion criteria: Breech presentation Antepartum haemorrhage Severe pre-eclampsia Aortic stenosis Cephalopelvic disproportions Coagulation defects or anticoagulant therapy Vertebral deformity Sensitivity of the drug to be administered Fetal distress

Design outcomes

Primary

MeasureTime frame
Onset of analgesia Duration of analgesia Duration of first stage Duration of second stage Dose given in each top-up Total top-upsTimepoint: Outcome to be studied during and immediately after completion of study Time taken in hours

Secondary

MeasureTime frame
Type of Delivery Normal Delivery Caesarian section Instrumental Delivery Complications during analgesia in labour Nausea Vomiting Pruritis Urinary retention Apgar score of neonate -1 min -5 min Any Fetal distressTimepoint: Outcome to be studied during and immediately after completion of study Time taken in hours

Countries

India

Contacts

Public ContactDr Satinder Kaur
tspunia@yahoo.com9417023131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026